INFO & CONTACTS:  +39 02 2390 1

A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors.

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Cresta Sara

Main Facility: Oncologia Medica 1

Drug: BNT326

BNT327

Pathologies: Colorectal cancer (CRC), Melanoma, Lung cancer, Breast cancer, Cervical tumor, Stomach tumors

ClinicalTrials.gov: Read more about clinical trials

This is a Phase I/II, multi-site, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose, and pharmacokinetics of BNT326 as monotherapy and in combination treatment with immunotherapies in adults with advanced solid tumors. 

In Part 1 participants will be treated with BNT326 (also known as YL202), a human epidermal growth factor receptor (HER)3-targeting antibody-drug conjugate (ADC) with a topoisomerase-1 inhibitor cytotoxic payload.  

In Part 2 BNT326 will be administered in combination with BNT327 (also known as pumitamig, BMS-986545, or PM8002), a bispecific antibody that acts on both programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF)-A proteins to relieve immunosuppression in the tumor microenvironment, reduce angiogenesis and normalize existing vasculature. 

Last update: 12/05/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe